2023
Trends in new and persistent opioid use in older adults with and without cancer
Baum L, KC M, Soulos P, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Trends in new and persistent opioid use in older adults with and without cancer. Journal Of The National Cancer Institute 2023, 116: 316-323. PMID: 37802882, DOI: 10.1093/jnci/djad206.Peer-Reviewed Original ResearchAdditional opioid useNew opioid useOpioid useNon-metastatic cancerPersistent opioid useRetrospective cohort studySolid tumor malignanciesClinical strataEligible patientsNaïve patientsOpioid prescribingMetastatic patientsSurgery patientsCohort studySEER-MedicareMetastatic cancerPatientsTumor malignancyCancerOlder adultsSurgeryRandom sampleAdditional useChemotherapyPrescribing
2022
Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma
Pritchard JE, Wilson LE, Miller SM, Greiner MA, Cohen HJ, Kaye DR, Zhang T, Dinan MA. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. Journal Of The American Geriatrics Society 2022, 70: 2330-2343. PMID: 35499667, PMCID: PMC9378524, DOI: 10.1111/jgs.17826.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaOral anticancer agentsRenal cell carcinomaMRCC diagnosisCognitive impairmentCell carcinomaFive-year survival rateSEER-Medicare patientsMedicare Part D coveragePart D coverageMild cognitive impairmentMRCC patientsMRCC treatmentEligible patientsOlder patientsTreatment initiationKidney cancerAgent useOAA treatmentPatientsStage IVSurvival rateNew casesDiagnosisD diagnosis
2021
Mediators of racial disparity in the use of prostate MRI.
Leapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. Mediators of racial disparity in the use of prostate MRI. Journal Of Clinical Oncology 2021, 39: 6554-6554. DOI: 10.1200/jco.2021.39.15_suppl.6554.Peer-Reviewed Original ResearchProstate cancerRacial disparitiesProstate MRIMRI useArea-level measuresObserved racial disparitiesEligible patientsPathologic factorsDual eligibilityWhite patientsBlack patientsSEER regionMedicare databaseCancer careSix-month periodPatientsSociodemographic factorsCancerMRIZip codesOlder AmericansMediatorsDiagnostic toolObserved disparitiesHigh-poverty areas